Quince Therapeutics

EryDel, based in Urbino, has developed a patented technology for drug delivery utilizing erythrocytes, or red blood cells. This innovative approach enables the efficient loading of red blood cells with various therapeutic agents, including drugs, proteins, and nanoparticles, which can be gradually released into the patient's body. The technology enhances treatment efficacy while minimizing side effects, particularly for chronic conditions that typically require daily medication. EryDel's solution has undergone testing in patients suffering from Inflammatory Bowel Diseases such as ulcerative colitis and Crohn's disease. Additionally, the company provides comprehensive support for the drug delivery process through its specialized device, the "Red Cell Loader," and associated disposable kits. This system aims to streamline blood processing at the point of care, enabling healthcare professionals to deliver therapies for a range of conditions efficiently.

Novosteo Inc. is a biotechnology company based in West Lafayette, Indiana, founded in 2017. The firm specializes in developing and manufacturing innovative drugs aimed at healing bone fractures and addressing related conditions that significantly impact patients' morbidity, mortality, and quality of life. With scientific guidance from co-founders Stewart Low and Philip Low of Purdue University, Novosteo utilizes a proprietary chemistry approach to bone targeting, which allows for the delivery of anabolic agents directly to fracture surfaces. This unique method focuses on accelerating bone regeneration and improving healing outcomes, thereby mitigating the debilitating effects associated with bone injuries and enhancing patient mobility and productivity.